STOCK TITAN

Twist Bioscience - TWST STOCK NEWS

Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.

Twist Bioscience Corporation (TWST) is a leader in synthetic DNA production, utilizing a proprietary semiconductor-based platform to drive innovations across biotechnology and healthcare. This page provides investors and industry professionals with timely, accurate updates on TWST's strategic developments and operational milestones.

Access consolidated press releases and news covering earnings announcements, product launches, research breakthroughs, and partnerships. Our curated updates ensure you stay informed about TWST's advancements in gene synthesis, high-throughput manufacturing, and applications in precision medicine.

Key content includes quarterly financial results, regulatory filings, technology patents, and collaborations with academic or industry partners. All materials are sourced directly from verified company communications to maintain factual integrity.

Bookmark this page for streamlined access to TWST's evolving role in synthetic biology. Check regularly for critical updates impacting market positioning and technological leadership in DNA synthesis.

Rhea-AI Summary

Twist Bioscience (TWST) has launched Twist Multiplexed Gene Fragments (MGFs), pools of directly synthesized double-stranded DNA up to 500 base pairs in length, with no limit on sequence number, enabling high-throughput screening applications. This offering allows for rapid screening of diverse targets for CRISPR and genome engineering, antibody discovery, protein engineering, and more. The customizable fragments have a quick turnaround time, starting at 8 business days, making them versatile for various applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.94%
Tags
none
-
Rhea-AI Summary

Twist Bioscience announced the granting of 87,200 restricted stock units to 26 new employees as inducement for joining the company. The RSUs vest over a 48-month period for each employee, with 25% vesting on the one year anniversary of employment and 1/16 vesting quarterly thereafter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.01%
Tags
none
-
Rhea-AI Summary

Twist Bioscience (NASDAQ: TWST) reported a record revenue of $75.3M in the second quarter of fiscal 2024, showing a 25% increase over the same period in fiscal 2023. Orders also grew by 45% to $93.2M. The company increased its revenue guidance for fiscal 2024 to a range of $300M to $304M and its gross margin guidance to 41.5% to 42.0%. Twist Bioscience continues to focus on profitability and aims to improve gross margin to over 50% by the end of fiscal 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.74%
Tags
Rhea-AI Summary
Twist Bioscience (NASDAQ: TWST) will report its fiscal 2024 second-quarter financial results on May 2, 2024, after the market closes. The company will host a conference call at 4:30 p.m. ET to discuss the results and provide a business update. The press release and webcast will be accessible on the company's website. Telephone participants can register on the Investor Relations website to receive the dial-in number and unique PIN for access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
conferences earnings
-
Rhea-AI Summary
Twist Bioscience (NASDAQ: TWST) launches a new Human Pangenome Spike-in for the Twist Exome 2.0 panel to enhance genetic variation detection during whole exome sequencing. The tool aims to provide a more comprehensive view of human genetic diversity, leveraging the Human Pangenome Reference Consortium's diverse genomic data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
none
-
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) announces CE-marked Precision Dx Products compliant with EU IVDR regulations, including Twist Precision Prep and Enrichment Dx Kit, Twist Precision Exome Dx Panel, and Twist Precision Exome Dx Kit. The products aim to facilitate panel sequencing within clinical settings, meeting high quality standards. Twist collaborates with Platomics to streamline documentation generation and regulatory compliance. CEO Emily M. Leproust highlights the significance of IVDR certification for diagnostic tests and the company's commitment to supporting European customers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
none
Rhea-AI Summary
Twist Bioscience Corporation (TWST) executives will participate in fireside chats at upcoming investor conferences, including TD Cowen 44th Annual Health Care Conference and Barclays 26th Annual Global Healthcare Conference. The chats will be webcast live and available for replay for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
conferences
-
Rhea-AI Summary
Twist Bioscience Corporation (TWST) announced the grant of 122,400 restricted stock units (RSUs) to 36 recently hired individuals as an employment inducement. The RSUs vest over a 48-month period, with 25% vesting on the one year anniversary of the start date of the employee, and 1/16 of the RSUs vesting on each quarterly anniversary thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
none
-
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) and Element Biosciences, Inc. announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System. The collaboration aims to offer customers an economical and streamlined approach to next generation sequencing. The Exome 2.0 panel and high performing library preparation and target enrichment reagents are designed to provide best-in-class sequencing, detect rare and inherited diseases, and germline cancers. The purpose-built solution for Element’s AVITI chemistry will reduce per sample sequencing requirements, potentially saving downstream sequencing costs. The companies have ambitious product roadmaps for 2024 to make sequencing even easier for labs to produce the highest quality data at a low cost.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
none
Rhea-AI Summary
Twist Bioscience Corporation (TWST) has launched the cfDNA Library Preparation Kit to enable liquid biopsy research, addressing challenges associated with library preparation from circulating cfDNA with reliable and robust performance from as little as 1ng sample input. The kit can detect rare allele variants due to its high conversion rate and protocols minimize sample handling for a streamlined workflow and results delivered within two hours.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
none
Twist Bioscience

Nasdaq:TWST

TWST Rankings

TWST Stock Data

2.20B
58.41M
2.16%
112.29%
15.59%
Diagnostics & Research
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO